Oxford Scientists Race to Develop Bundibugyo Ebola Vaccine Ahead of Potential Crisis

Oxford Scientists Fast-Track Ebola Vaccine Amid Growing Outbreak Concerns

Researchers at Oxford University are urgently developing a new vaccine targeting a rare and deadly strain of the Ebola virus, with clinical trials potentially beginning within two to three months. The effort comes in direct response to a worsening outbreak centered in the Democratic Republic of Congo, where 750 suspected cases and 177 deaths have already been recorded.

A Deadly Strain With No Proven Vaccine

The current outbreak is caused by the Bundibugyo species of the Ebola virus — a rare strain that has only triggered two previous outbreaks, one in Uganda in 2007 and another in the DR Congo in 2012. The virus has not been detected for over a decade, and unlike the more common Zaire strain of Ebola, there is currently no approved vaccine to combat it. Bundibugyo is particularly dangerous, killing approximately one in three people it infects.

The World Health Organization (WHO) has elevated the outbreak's risk level within the DR Congo from "high" to "very high," while classifying the regional risk as high and the international risk as low. Following a public health emergency of international concern declared on Sunday, the WHO was careful to clarify that the outbreak does not constitute a pandemic.

The Technology Behind the Vaccine

The Oxford-developed vaccine leverages the same platform used to create the university's widely distributed Covid-19 vaccine. Known as ChAdOx1, this highly adaptable technology can be rapidly modified to target different infectious diseases. During the coronavirus pandemic, the platform was loaded with genetic material from the Covid-19 virus. This time, it has been encoded with genetic information specific to the Bundibugyo Ebola strain.

The vaccine works by using a genetically engineered version of a common cold virus that naturally infects chimpanzees. Scientists have modified this virus to make it safe for human use, then use it as a delivery vehicle to introduce key genetic information about the Bundibugyo pathogen into human cells. This process effectively trains the immune system to recognize and neutralize the actual disease without causing any Ebola infection or symptoms.

Animal Trials Already Underway

While significant uncertainty remains, animal testing is currently in progress at Oxford. The WHO has noted that no animal data confirming the vaccine's effectiveness has yet been published, but the organization acknowledged that doses could potentially be ready for human clinical trials within two to three months — depending heavily on the outcomes of those animal studies.

A second, separate experimental vaccine targeting Bundibugyo is also under development, though that candidate is expected to take considerably longer — approximately six to nine months — before it is ready for testing.

Mass Production Plans Already in Place

In a sign of the seriousness with which researchers are approaching the situation, the Serum Institute of India has already been designated as the manufacturing partner to produce the Oxford vaccine at scale once the research team provides medical-grade starting material.

Professor Katie Lambe, Calleva Head of Vaccine Immunology at the Oxford Vaccine Group, emphasized the scale of what's possible: "Once we get starting material to them they can go fast and they can go big."

She also stressed the urgency driving the team's work: "People are worried about this outbreak. Generally, you prepare for the worst-case scenario — hopefully contact tracing and quarantine is all that's needed, but we can't take our foot off the gas."

How the Vaccine Would Be Deployed

Unlike mass vaccination campaigns seen during the Covid-19 pandemic, an Ebola vaccine would be administered using a targeted strategy known as ring vaccination. This approach focuses immunization efforts on the individuals most at risk — primarily the close contacts of confirmed Ebola cases and healthcare workers treating infected patients, who face extremely high exposure risks.

Of the six known species of the Ebola virus, only three are responsible for large-scale human outbreaks. The Oxford team has been building expertise in this area for some time, having previously worked on experimental vaccines for both the Sudan strain of Ebola and the closely related Marburg virus. That foundational work is now helping accelerate the development of a potential Bundibugyo solution at a critical moment.